Galderma set to launch Nuvo's Pliaglis in EU
This article was originally published in Scrip
Executive Summary
Dermatology company Galderma has received its first three EU marketing licences for its topical pain drug Pliaglis (tetracaine and lidocaine), with plans to launch in the first half of 2013.
You may also be interested in...
Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.